Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report

Table 1 Previous case reports of patients with colorectal cancer and hyperbilirubinaemia treated with anti-EGFR antibodies with or without cytotoxic agents

Age (yr), gender	ECOG PS	Primary site	KRAS	Previous treatment	Total bilirubin (mg/dL)	Treatment	Overall survival (month)
63, M[16]	2	Unknown	WT	FOLFIRI, FOLFOX	2.5	Cetuximab	1.3
66, M[16]	2	Unknown	WT	IRIS, FOLFOX + Bevacizumab	2.3	Cetuximab	3.1
65, M[16]	2	Unknown	WT	FOLFIRI, FOLFOX	2.6	Cetuximab	5.9
45, F[16]	3	Unknown	WT	FOLFOX, FOLFIRI + Bevacizumab	7.9	Cetuximab	2.8
56, F[16]	1	Unknown	WT	FOLFOX, FOLFIRI + Bevacizumab	13	Cetuximab	2.6
69, M[16]	3	Unknown	WT	Irinotecan	7.4	Cetuximab	1.2
78, M[16]	2	Unknown	MT	FOLFOX + Bevacizumab, FOLFIRI	9.7	Cetuximab	0.5
43, M[9]	3	Right	WT	No	9.4	FOLFOX + Panitumuab	1.5
48, M[17]	Unknown	Left	WT	No	6.2	FOLFOX + Cetuximab	≥ 7

M: Male; F: Female; ECOG: Eastern Cooperative Oncology Group; PS: Performance status; WT: Wild type.